Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

The point of care hematology diagnostics sector has experienced significant growth recently, driven by the need for quicker and more accessible blood testing solutions. As healthcare systems evolve and demand for rapid diagnostics increases, this market is set to see continued expansion in the coming years. Here, we explore the market’s current status, key growth drivers, segmentation, technological trends, leading companies, and regional performance.

Forecasted Expansion and Market Size of the Point of Care Hematology Diagnostics Market

The market for point of care hematology diagnostics has shown strong growth momentum and is anticipated to rise from $2.9 billion in 2025 to $3.16 billion in 2026, growing at a compound annual rate of 9.0%. This growth during the historical period is attributed to reliance on centralized lab testing, an increasing prevalence of anemia and other blood-related disorders, rising hospital emergency admissions, the necessity for faster diagnosis, and limited laboratory access in rural locations. Looking ahead, the market is expected to reach $4.39 billion by 2030, with a CAGR of 8.6%. Factors fueling this future growth include the rising incidence of chronic and infectious diseases, expansion of point of care testing programs, heightened demand for rapid diagnostics in emergency scenarios, technological advances in compact hematology analyzers, and the shift toward decentralized healthcare models. Important trends during this period encompass the growing use of rapid bedside blood testing, increased demand for decentralized diagnostics in urgent care settings, adoption of portable and handheld devices, expansion into resource-limited areas, and a focus on reducing turnaround times for clinical decisions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27388&type=smp

Increasing Prevalence of Blood Disorders as a Growth Catalyst in the Point of Care Hematology Diagnostics Market

A major factor propelling the point of care hematology diagnostics market is the rise in blood disorders, which affect components such as red and white blood cells, platelets, and plasma. The growing burden of chronic diseases directly impacts blood health, necessitating regular monitoring. Point of care diagnostics provide timely and accurate results near the patient, enabling faster treatment decisions and better disease management. For example, in November 2024, the American Society of Hematology projected that global leukemia cases could reach approximately 519,540 by 2050. This increase in blood disorder prevalence is a key driver encouraging market expansion.

How Chronic Disease Trends Support the Point of Care Hematology Diagnostics Growth

Chronic diseases increase the demand for continuous blood monitoring, which fuels the need for rapid and accessible hematology diagnostics at the point of care. This trend is expected to push healthcare providers toward adopting more decentralized testing solutions to manage patient health efficiently. Additionally, the amplified burden on emergency departments due to such conditions necessitates quicker diagnostic methods, further stimulating demand for portable hematology devices.

Access The Complete Point Of Care Hematology Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/point-of-care-hematology-diagnostics-global-market-report

Detailed Segmentation of the Point of Care Hematology Diagnostics Market

The report categorizes the point of care hematology diagnostics market into several segments:

1) By Type: Complete Blood Count (CBC), Coagulation Testing, Hemoglobin Testing, Anemia Diagnosis, and Other Types

2) By Mode of Prescription: Prescription-Based Products and Over-The-Counter Products

3) By End User: Diagnostic Centers, Hospitals, Blood Banks, Transfusion Centers, and Other End Users

Further subsegments include:

– Complete Blood Count (CBC) components such as White Blood Cell Count, Red Blood Cell Count, Platelet Count, Hematocrit, Hemoglobin Concentration, and Mean Corpuscular Volume (MCV)

– Coagulation Testing elements including Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), International Normalized Ratio (INR), D-Dimer Test, and Fibrinogen Level

– Hemoglobin Testing types like Total Hemoglobin, Glycated Hemoglobin (HbA1c), Oxyhemoglobin, Carboxyhemoglobin, and Methemoglobin

– Anemia Diagnosis tests such as Iron Studies, Vitamin B12 Levels, Folate Levels, Reticulocyte Count, Ferritin Test, and Transferrin Saturation

– Other types including Blood Typing and Crossmatching, Erythrocyte Sedimentation Rate, Malaria Parasite Detection, Sickle Cell Screening, and C-Reactive Protein Testing

Innovations Shaping Future Demand in the Point of Care Hematology Diagnostics Market

Leading companies in this field are focusing on launching technologically advanced products like cartridge-based AI-powered hematology analyzers. These compact devices utilize single-use reagent cartridges combined with artificial intelligence algorithms to provide quick, precise blood analysis directly at the patient’s location. For instance, in September 2024, Zoetis Inc., a US veterinary health firm, introduced Vetscan OptiCell—a cartridge-based, AI-enhanced hematology analyzer designed for veterinary applications. This system delivers rapid, laboratory-quality complete blood count (CBC) results within minutes, reduces maintenance needs, and features advanced AI-driven image processing and viscoelastic focusing technology. These features enable accurate blood cell classification and automated detection of abnormalities, promoting efficient and reliable diagnostics in veterinary care.

Key Players Dominating the Point of Care Hematology Diagnostics Market

Several prominent companies lead the point of care hematology diagnostics space, including F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Sysmex Corporation, HORIBA Ltd., Nova Biomedical Corp., S.D. Sight Diagnostics Ltd., EKF Diagnostics Holdings plc., BioMedomics Inc., PixCell Medical Technologies Ltd., Boule Diagnostics AB, Nihon Kohden Corporation, Edan Instruments Inc., A Menarini Industrie Farmaceutiche Srl, Becton Dickinson and Company, Ortho Clinical Diagnostics, Khema Diagnostics, and Bio-Rad Laboratories Inc.

Regional Analysis Highlighting Market Leadership and Growth Potential

In 2025, North America stood as the largest market for point of care hematology diagnostics. However, Asia-Pacific is forecasted to experience the highest growth rate over the upcoming years. The market report covers key regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a broad perspective on global market dynamics.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model